JP2013542996A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013542996A5 JP2013542996A5 JP2013539970A JP2013539970A JP2013542996A5 JP 2013542996 A5 JP2013542996 A5 JP 2013542996A5 JP 2013539970 A JP2013539970 A JP 2013539970A JP 2013539970 A JP2013539970 A JP 2013539970A JP 2013542996 A5 JP2013542996 A5 JP 2013542996A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- independently
- item
- aryl
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 730
- 150000001875 compounds Chemical class 0.000 claims description 346
- 125000001188 haloalkyl group Chemical group 0.000 claims description 244
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 100
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 84
- 150000003839 salts Chemical class 0.000 claims description 45
- 125000005170 cycloalkyloxycarbonyl group Chemical group 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 125000006254 cycloalkyl carbonyl group Chemical group 0.000 claims description 10
- 239000002777 nucleoside Substances 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- 208000005176 Hepatitis C Diseases 0.000 claims description 6
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 6
- 239000003112 inhibitor Substances 0.000 claims description 5
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- IWUCXVSUMQZMFG-RGDLXGNYSA-N 1-[(2s,3s,4r,5s)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazole-3-carboxamide Chemical compound N1=C(C(=O)N)N=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 IWUCXVSUMQZMFG-RGDLXGNYSA-N 0.000 claims description 2
- 101001023866 Arabidopsis thaliana Mannosyl-oligosaccharide glucosidase GCS1 Proteins 0.000 claims description 2
- 101800001838 Serine protease/helicase NS3 Proteins 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 2
- 229960000329 ribavirin Drugs 0.000 claims description 2
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims description 2
- NHKZSTHOYNWEEZ-AFCXAGJDSA-N taribavirin Chemical compound N1=C(C(=N)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NHKZSTHOYNWEEZ-AFCXAGJDSA-N 0.000 claims description 2
- 229950006081 taribavirin Drugs 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000000178 monomer Substances 0.000 claims 2
- TZYVRXZQAWPIAB-FCLHUMLKSA-N 5-amino-3-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4h-[1,3]thiazolo[4,5-d]pyrimidine-2,7-dione Chemical compound O=C1SC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O TZYVRXZQAWPIAB-FCLHUMLKSA-N 0.000 claims 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- 229960002897 heparin Drugs 0.000 claims 1
- 229920000669 heparin Polymers 0.000 claims 1
- 229950003954 isatoribine Drugs 0.000 claims 1
- 150000003017 phosphorus Chemical class 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 description 419
- 125000003118 aryl group Chemical group 0.000 description 379
- 125000003710 aryl alkyl group Chemical group 0.000 description 242
- 125000003545 alkoxy group Chemical group 0.000 description 179
- 125000005843 halogen group Chemical group 0.000 description 161
- 125000000753 cycloalkyl group Chemical group 0.000 description 152
- -1 cyclopropylcarbonylamino Chemical group 0.000 description 132
- 125000003342 alkenyl group Chemical group 0.000 description 111
- 229910052739 hydrogen Inorganic materials 0.000 description 109
- 239000001257 hydrogen Substances 0.000 description 109
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 105
- 125000004429 atom Chemical group 0.000 description 98
- 229910052799 carbon Inorganic materials 0.000 description 96
- 125000004438 haloalkoxy group Chemical group 0.000 description 88
- 125000004966 cyanoalkyl group Chemical group 0.000 description 86
- 125000004415 heterocyclylalkyl group Chemical group 0.000 description 85
- 229910052717 sulfur Inorganic materials 0.000 description 82
- 125000004103 aminoalkyl group Chemical group 0.000 description 80
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 description 80
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 79
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 79
- 125000000304 alkynyl group Chemical group 0.000 description 76
- 125000003302 alkenyloxy group Chemical group 0.000 description 75
- 125000004994 halo alkoxy alkyl group Chemical group 0.000 description 74
- 125000005844 heterocyclyloxy group Chemical group 0.000 description 74
- 125000005099 aryl alkyl carbonyl group Chemical group 0.000 description 72
- 125000005129 aryl carbonyl group Chemical group 0.000 description 70
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 70
- 125000006517 heterocyclyl carbonyl group Chemical group 0.000 description 69
- 125000004043 oxo group Chemical group O=* 0.000 description 69
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 69
- 125000000278 alkyl amino alkyl group Chemical group 0.000 description 67
- 150000001721 carbon Chemical group 0.000 description 62
- 125000000033 alkoxyamino group Chemical group 0.000 description 61
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 57
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 56
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 52
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 52
- 125000001424 substituent group Chemical group 0.000 description 49
- 229910052760 oxygen Inorganic materials 0.000 description 46
- 125000004963 sulfonylalkyl group Chemical group 0.000 description 44
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 description 43
- 125000000000 cycloalkoxy group Chemical group 0.000 description 43
- 125000005143 heteroarylsulfonyl group Chemical group 0.000 description 42
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 41
- 150000004678 hydrides Chemical class 0.000 description 40
- 125000005098 aryl alkoxy carbonyl group Chemical group 0.000 description 35
- 125000005324 aryloxy alkyloxy group Chemical group 0.000 description 35
- 125000005180 haloalkoxyalkyloxy group Chemical group 0.000 description 35
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 34
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 34
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 30
- 229940002612 prodrug Drugs 0.000 description 30
- 239000000651 prodrug Substances 0.000 description 30
- 125000005083 alkoxyalkoxy group Chemical group 0.000 description 28
- 125000005159 cyanoalkoxy group Chemical group 0.000 description 28
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 26
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 25
- 125000005842 heteroatom Chemical group 0.000 description 23
- 125000004702 alkoxy alkyl carbonyl group Chemical group 0.000 description 22
- 150000002431 hydrogen Chemical class 0.000 description 22
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical group C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 22
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 22
- 125000005339 cyanocycloalkoxy group Chemical group 0.000 description 21
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 21
- 125000004993 haloalkoxycarbonyl group Chemical group 0.000 description 21
- 125000001072 heteroaryl group Chemical group 0.000 description 20
- 125000005093 alkyl carbonyl alkyl group Chemical group 0.000 description 14
- 125000004686 alkyl sulfanyl alkyl group Chemical group 0.000 description 14
- 125000005160 aryl oxy alkyl group Chemical group 0.000 description 14
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 14
- 125000005144 cycloalkylsulfonyl group Chemical group 0.000 description 14
- 125000004449 heterocyclylalkenyl group Chemical group 0.000 description 14
- 125000005182 hydroxyalkylcarbonyl group Chemical group 0.000 description 14
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 9
- 125000005092 alkenyloxycarbonyl group Chemical group 0.000 description 8
- 241000239366 Euphausiacea Species 0.000 description 7
- 125000005078 alkoxycarbonylalkyl group Chemical group 0.000 description 7
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 description 7
- 125000004414 alkyl thio group Chemical group 0.000 description 7
- 125000004181 carboxyalkyl group Chemical group 0.000 description 7
- 125000005553 heteroaryloxy group Chemical group 0.000 description 7
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 7
- 125000004008 6 membered carbocyclic group Chemical group 0.000 description 6
- 125000005282 allenyl group Chemical group 0.000 description 6
- 125000004858 cycloalkoxyalkyl group Chemical group 0.000 description 6
- 125000004433 nitrogen atom Chemical group N* 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- 125000006661 (C4-C6) heterocyclic group Chemical group 0.000 description 5
- 102000014150 Interferons Human genes 0.000 description 5
- 108010050904 Interferons Proteins 0.000 description 5
- 229940079322 interferon Drugs 0.000 description 5
- LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 125000000165 tricyclic carbocycle group Chemical group 0.000 description 4
- 125000000169 tricyclic heterocycle group Chemical group 0.000 description 4
- 125000002619 bicyclic group Chemical group 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 2
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical group O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001024304 Mino Species 0.000 description 1
- 241001553014 Myrsine salicina Species 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 229940123066 Polymerase inhibitor Drugs 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical group O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000013160 medical therapy Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41481810P | 2010-11-17 | 2010-11-17 | |
| US61/414,818 | 2010-11-17 | ||
| US201161504924P | 2011-07-06 | 2011-07-06 | |
| US61/504,924 | 2011-07-06 | ||
| PCT/US2011/060966 WO2012068234A2 (en) | 2010-11-17 | 2011-11-16 | Antiviral compounds |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016051146A Division JP2016106149A (ja) | 2010-11-17 | 2016-03-15 | 抗ウイルス化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013542996A JP2013542996A (ja) | 2013-11-28 |
| JP2013542996A5 true JP2013542996A5 (enExample) | 2015-01-08 |
| JP5905020B2 JP5905020B2 (ja) | 2016-04-20 |
Family
ID=45099196
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013539970A Active JP5905020B2 (ja) | 2010-11-17 | 2011-11-16 | 抗ウイルス化合物 |
| JP2016051146A Pending JP2016106149A (ja) | 2010-11-17 | 2016-03-15 | 抗ウイルス化合物 |
| JP2017240524A Withdrawn JP2018039851A (ja) | 2010-11-17 | 2017-12-15 | 抗ウイルス化合物 |
| JP2019206819A Withdrawn JP2020037584A (ja) | 2010-11-17 | 2019-11-15 | 抗ウイルス化合物 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016051146A Pending JP2016106149A (ja) | 2010-11-17 | 2016-03-15 | 抗ウイルス化合物 |
| JP2017240524A Withdrawn JP2018039851A (ja) | 2010-11-17 | 2017-12-15 | 抗ウイルス化合物 |
| JP2019206819A Withdrawn JP2020037584A (ja) | 2010-11-17 | 2019-11-15 | 抗ウイルス化合物 |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US9156823B2 (enExample) |
| EP (3) | EP3699176A3 (enExample) |
| JP (4) | JP5905020B2 (enExample) |
| KR (5) | KR20190140486A (enExample) |
| AR (1) | AR083711A1 (enExample) |
| AU (3) | AU2011328980B2 (enExample) |
| CA (3) | CA2817840A1 (enExample) |
| ES (1) | ES2634095T3 (enExample) |
| HK (1) | HK1250162A1 (enExample) |
| IL (1) | IL226346A (enExample) |
| NZ (2) | NZ726475A (enExample) |
| PL (1) | PL2640719T3 (enExample) |
| PT (1) | PT2640719T (enExample) |
| SG (2) | SG10201509456SA (enExample) |
| SI (1) | SI2640719T1 (enExample) |
| TW (3) | TWI548629B (enExample) |
| UY (1) | UY33735A (enExample) |
| WO (1) | WO2012068234A2 (enExample) |
Families Citing this family (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI2604620T4 (fi) | 2003-05-30 | 2024-09-11 | Gilead Pharmasset Llc | Modifioituja fluorinoituja nukleosidianalogeja |
| LT2873665T (lt) | 2009-05-13 | 2016-10-25 | Gilead Pharmasset Llc | Antivirusiniai junginiai |
| RS52854B (sr) | 2009-06-11 | 2013-12-31 | Abbvie Bahamas Limited | Inhibitori hepatitis c virusa |
| US8937150B2 (en) | 2009-06-11 | 2015-01-20 | Abbvie Inc. | Anti-viral compounds |
| WO2011150243A1 (en) * | 2010-05-28 | 2011-12-01 | Presidio Pharmaceuticals, Inc. | Inhibitors of hcv ns5a |
| NZ605440A (en) | 2010-06-10 | 2014-05-30 | Abbvie Bahamas Ltd | Solid compositions comprising an hcv inhibitor |
| SI2640719T1 (sl) | 2010-11-17 | 2017-07-31 | Gilead Pharmasset Llc | Antivirusne spojine |
| US8552047B2 (en) | 2011-02-07 | 2013-10-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US9546160B2 (en) | 2011-05-12 | 2017-01-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
| KR101991298B1 (ko) | 2011-09-16 | 2019-06-21 | 길리애드 파마셋 엘엘씨 | Hcv 치료 방법 |
| EP3778606A3 (en) | 2011-11-16 | 2021-03-03 | Gilead Pharmasset LLC | Condensed imidazolylimidazoles as antiviral compounds |
| AU2015252077A1 (en) * | 2011-11-16 | 2015-11-19 | Gilead Pharmasset Llc | Antiviral compounds |
| US9034832B2 (en) | 2011-12-29 | 2015-05-19 | Abbvie Inc. | Solid compositions |
| US9326973B2 (en) | 2012-01-13 | 2016-05-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2013118097A1 (en) * | 2012-02-10 | 2013-08-15 | Lupin Limited | Antiviral compounds with a dibenzooxaheterocycle moiety |
| US9079887B2 (en) * | 2012-05-16 | 2015-07-14 | Gilead Sciences, Inc. | Antiviral compounds |
| US20130309196A1 (en) * | 2012-05-16 | 2013-11-21 | Gilead Sciences, Inc. | Antiviral compounds |
| US9233974B2 (en) * | 2012-12-21 | 2016-01-12 | Gilead Sciences, Inc. | Antiviral compounds |
| HUE047777T2 (hu) | 2013-01-31 | 2020-05-28 | Gilead Pharmasset Llc | Két vírusellenes vegyület kombinációs készítménye |
| CN105121428B (zh) | 2013-02-07 | 2019-12-24 | 九州有机光材股份有限公司 | 具有二氮杂苯并菲环结构的化合物和有机电致发光器件 |
| US11484534B2 (en) | 2013-03-14 | 2022-11-01 | Abbvie Inc. | Methods for treating HCV |
| WO2014185995A1 (en) * | 2013-05-16 | 2014-11-20 | Gilead Pharmasset Llc | Hepatitis c treatments with sofosbuvir |
| CN104211677B (zh) * | 2013-05-30 | 2018-02-23 | 浙江九洲药业股份有限公司 | 一种抗丙型肝炎药物中间体的制备方法 |
| CN104211565A (zh) * | 2013-05-31 | 2014-12-17 | 浙江九洲药业股份有限公司 | 一种抗丙型肝炎药物中间体的制备方法 |
| WO2014206257A1 (zh) | 2013-06-26 | 2014-12-31 | 浙江九洲药业股份有限公司 | 一种2-羧酸吡咯烷衍生物的制备方法 |
| US9717712B2 (en) | 2013-07-02 | 2017-08-01 | Bristol-Myers Squibb Company | Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus |
| US20150023913A1 (en) | 2013-07-02 | 2015-01-22 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| JP2016527232A (ja) | 2013-07-17 | 2016-09-08 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｈｃｖの治療に使用するためのビフェニル誘導体を含む組み合わせ |
| US20150064252A1 (en) * | 2013-08-27 | 2015-03-05 | Gilead Pharmasset Llc | Solid dispersion formulation of an antiviral compound |
| EP4005560A1 (en) * | 2013-08-27 | 2022-06-01 | Gilead Pharmasset LLC | Combination formulation of two antiviral compounds |
| CN104418784B (zh) * | 2013-09-04 | 2019-02-19 | 浙江九洲药业股份有限公司 | 一种抗病毒药物中间体的拆分方法 |
| WO2015089810A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Fused tetracyclic heterocyclic compounds and methods of use thereof for the treatment of viral diseases |
| WO2015101215A1 (zh) * | 2013-12-31 | 2015-07-09 | 南京圣和药业股份有限公司 | 9,9,10,10-四氟-9,10二氢菲类丙型肝炎病毒抑制剂及其应用 |
| EP3089757A1 (en) | 2014-01-03 | 2016-11-09 | AbbVie Inc. | Solid antiviral dosage forms |
| WO2015184644A1 (zh) * | 2014-06-06 | 2015-12-10 | 爱博新药研发(上海)有限公司 | 抑制丙肝病毒的化合物、药物组合物及其应用 |
| TW202014413A (zh) * | 2014-06-11 | 2020-04-16 | 美商基利法瑪席特有限責任公司 | 製備抗病毒化合物之方法 |
| TWI721947B (zh) | 2014-06-11 | 2021-03-21 | 美商基利法瑪席特有限責任公司 | 抗病毒化合物的固態形式 |
| ES2686352T3 (es) * | 2014-06-12 | 2018-10-17 | Gilead Sciences, Inc. | Compuestos antivíricos |
| HRP20211456T1 (hr) | 2014-12-26 | 2021-12-24 | Emory University | Protuvirusni derivati n4-hidroksicitidina |
| CN104592124B (zh) * | 2015-01-04 | 2018-01-02 | 华南理工大学 | 一种萘[1,2]并咪唑双极性共轭化合物及制备与应用 |
| TWI703141B (zh) * | 2015-03-12 | 2020-09-01 | 大陸商廣東東陽光藥業有限公司 | 作為丙型肝炎抑制劑的化合物及其在藥物中的應用 |
| CN106256819B (zh) * | 2015-06-19 | 2019-07-09 | 重庆博腾制药科技股份有限公司 | 一种(4S)-N-Boc-4-甲氧基甲基-L-脯氨酸胺盐的合成方法 |
| WO2016202232A1 (zh) * | 2015-06-19 | 2016-12-22 | 重庆博腾制药科技股份有限公司 | 一种(4S)-N-Boc-4-甲氧基甲基-L-脯氨酸胺盐的合成方法 |
| US10617675B2 (en) | 2015-08-06 | 2020-04-14 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| KR101919194B1 (ko) * | 2015-09-15 | 2018-11-15 | 주식회사 엘지화학 | 헤테로고리 화합물 및 이를 포함하는 유기 발광 소자 |
| WO2017181383A1 (en) * | 2016-04-21 | 2017-10-26 | Merck Sharp & Dohme Corp. | Hepatitis c virus inhibitors |
| EP3454856B1 (en) | 2016-05-10 | 2024-09-11 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| CN109641874A (zh) | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
| ES2990061T3 (es) | 2016-05-10 | 2024-11-28 | C4 Therapeutics Inc | Degronímeros espirocíclicos para la degradación de proteínas diana |
| WO2017197051A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Amine-linked c3-glutarimide degronimers for target protein degradation |
| KR102202984B1 (ko) | 2016-05-27 | 2021-01-13 | 길리애드 사이언시즈, 인코포레이티드 | Ns5a, ns5b 또는 ns3 억제제를 사용하여 b형 간염 바이러스 감염을 치료하는 방법 |
| CN106432197B (zh) * | 2016-09-07 | 2019-12-10 | 上海众强药业有限公司 | 一种雷迪帕韦中间体单对甲苯磺酸盐、其晶型及其制备方法 |
| CN107674064B (zh) * | 2016-11-30 | 2020-03-27 | 上海博志研新药物技术有限公司 | 维帕他韦中间体、制备方法及维帕他韦的制备方法 |
| WO2018138050A1 (de) | 2017-01-26 | 2018-08-02 | Bayer Aktiengesellschaft | Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel |
| EP3641762A4 (en) | 2017-06-20 | 2021-03-10 | C4 Therapeutics, Inc. | N / O-LINKED DEGRONES AND DEGRONIMERS FOR PROTEIN DEGRADATION |
| SG11202004403QA (en) | 2017-12-07 | 2020-06-29 | Univ Emory | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
| UA126458C2 (uk) | 2018-02-13 | 2022-10-05 | Гіліад Сайєнсіз, Інк. | Інгібітори pd-1/pd-l1 |
| US10899735B2 (en) | 2018-04-19 | 2021-01-26 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
| CN112638889A (zh) | 2018-05-15 | 2021-04-09 | 路易斯维尔大学研究基金会 | 用于治疗的尿石素a和其衍生物 |
| EP3820572B1 (en) | 2018-07-13 | 2023-08-16 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| AU2019366355B2 (en) | 2018-10-24 | 2022-10-13 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
| KR102316919B1 (ko) | 2019-11-28 | 2021-10-22 | 서울시립대학교 산학협력단 | 피지컬 컴퓨팅 소프트웨어를 이용한 코딩 교육 교재 및 이를 활용한 코딩 교육 방법 |
| CN111018870B (zh) * | 2019-11-29 | 2021-07-23 | 南京正济医药研究有限公司 | 一种维帕他韦中间体的制备方法 |
| US11091447B2 (en) | 2020-01-03 | 2021-08-17 | Berg Llc | UBE2K modulators and methods for their use |
| WO2021209563A1 (en) | 2020-04-16 | 2021-10-21 | Som Innovation Biotech, S.A. | Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus |
| CN112877379B (zh) * | 2021-01-18 | 2023-09-01 | 华南理工大学 | 一种化学酶法合成n-[(3r,6r)-6-甲基哌啶-3-基]氨基甲酸叔丁酯的方法 |
| WO2022246072A1 (en) * | 2021-05-21 | 2022-11-24 | Gilead Sciences, Inc. | Tetracyclic compounds for the treatment of zika virus infection |
| CN117460734A (zh) * | 2021-05-21 | 2024-01-26 | 吉利德科学公司 | 作为寨卡病毒抑制剂的五环衍生物 |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816570A (en) | 1982-11-30 | 1989-03-28 | The Board Of Regents Of The University Of Texas System | Biologically reversible phosphate and phosphonate protective groups |
| US4968788A (en) | 1986-04-04 | 1990-11-06 | Board Of Regents, The University Of Texas System | Biologically reversible phosphate and phosphonate protective gruops |
| DE69115694T2 (de) | 1990-06-13 | 1996-10-17 | Arnold Newton Mass. Glazier | Phosphorylierte prodrugs |
| DE69129650T2 (de) | 1990-09-14 | 1999-03-25 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic, Prag/Praha | Wirkstoffvorläufer von Phosphonaten |
| US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
| US5858389A (en) | 1996-08-28 | 1999-01-12 | Shaker H. Elsherbini | Squalene is an antiviral compound for treating hepatitis C virus carriers |
| JP4558314B2 (ja) | 2001-07-20 | 2010-10-06 | ベーリンガー インゲルハイム （カナダ） リミテッド | ウイルスポリメラーゼインヒビター |
| MXPA05012101A (es) | 2003-05-09 | 2006-02-08 | Boehringer Ingelheim Int | Bolsillo de union al inhibidor de polimerasa ns5b del virus de la hepatitis c. |
| US7157492B2 (en) | 2004-02-26 | 2007-01-02 | Wyeth | Dibenzo chromene derivatives and their use as ERβ selective ligands |
| HRP20070043A2 (hr) | 2004-07-16 | 2007-07-31 | Gilead Sciences | Antivirusna sredstva |
| WO2006089231A2 (en) * | 2005-02-18 | 2006-08-24 | Medarex, Inc. | Monoclonal antibodies against prostate specific membrane antigen (psma) lacking in fucosyl residues |
| US8891379B2 (en) | 2006-06-02 | 2014-11-18 | Riverbed Technology, Inc. | Traffic flow inference based on link loads and gravity measures |
| US7659270B2 (en) * | 2006-08-11 | 2010-02-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7759495B2 (en) * | 2006-08-11 | 2010-07-20 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8329159B2 (en) | 2006-08-11 | 2012-12-11 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| JPWO2008069262A1 (ja) | 2006-12-07 | 2010-03-25 | 第一三共株式会社 | 安定性が改善されたフィルムコーティング製剤 |
| US7741347B2 (en) | 2007-05-17 | 2010-06-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| SI2250163T1 (sl) * | 2008-02-12 | 2012-08-31 | Bristol Myers Squibb Co | Hepatitis c virus inhibitorji |
| US8147818B2 (en) * | 2008-02-13 | 2012-04-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| NZ587557A (en) * | 2008-02-13 | 2012-04-27 | Bristol Myers Squibb Co | Imidazolyl biphenyl imidazoles as hepatitis c virus inhibitors |
| US7704992B2 (en) | 2008-02-13 | 2010-04-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US20100256184A1 (en) | 2008-08-13 | 2010-10-07 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
| US8729077B2 (en) * | 2008-11-28 | 2014-05-20 | Glaxosmithkline Llc | Anti-viral compounds, compositions, and methods of use |
| JP2012510525A (ja) | 2008-12-03 | 2012-05-10 | プレシディオ ファーマシューティカルズ インコーポレイテッド | Ｈｃｖｎｓ５ａの阻害剤 |
| EP2398474A4 (en) * | 2009-02-23 | 2012-12-05 | Presidio Pharmaceuticals Inc | HCV NS5A SHEMMER |
| WO2010099527A1 (en) * | 2009-02-27 | 2010-09-02 | Enanta Pharmaceuticals, Inc. | Hepatitis c virus inhibitors |
| US8709999B2 (en) | 2009-03-27 | 2014-04-29 | Presidio Pharmaceuticals, Inc. | Substituted bicyclic HCV inhibitors |
| SG174883A1 (en) | 2009-03-27 | 2011-11-28 | Presidio Pharmaceuticals Inc | Fused ring inhibitors of hepatitis c |
| US9139569B2 (en) | 2009-05-12 | 2015-09-22 | Merck Sharp & Dohme Corp. | Fused tricyclic aryl compounds useful for the treatment of viral diseases |
| LT2873665T (lt) * | 2009-05-13 | 2016-10-25 | Gilead Pharmasset Llc | Antivirusiniai junginiai |
| US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
| US8138215B2 (en) * | 2009-05-29 | 2012-03-20 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| CA2771327A1 (en) * | 2009-09-04 | 2011-03-10 | Glaxosmithkline Llc | Chemical compounds |
| EP2475256A4 (en) * | 2009-09-11 | 2013-06-05 | Enanta Pharm Inc | HEPATITIS C-VIRUS HEMMER |
| US20120276047A1 (en) | 2009-11-25 | 2012-11-01 | Rosenblum Stuart B | Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases |
| US8377980B2 (en) * | 2009-12-16 | 2013-02-19 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2011075607A1 (en) | 2009-12-18 | 2011-06-23 | Intermune, Inc. | Novel inhibitors of hepatitis c virus replication |
| AU2010341537A1 (en) | 2009-12-22 | 2012-08-09 | Merck Sharp & Dohme Corp. | Fused Tricyclic Compounds and methods of use thereof for the treatment of viral diseases |
| US8609635B2 (en) * | 2010-03-09 | 2013-12-17 | Merck Sharp & Dohme Corp. | Fused tricyclic silyl compounds and methods of use thereof for the treatment of viral diseases |
| US9125904B1 (en) * | 2010-05-11 | 2015-09-08 | Achillion Pharmaceuticals, Inc. | Biphenyl imidazoles and related compounds useful for treating HCV infections |
| US20110312996A1 (en) | 2010-05-17 | 2011-12-22 | Intermune, Inc. | Novel inhibitors of hepatitis c virus replication |
| EP2616461A4 (en) * | 2010-08-26 | 2014-03-26 | Rfs Pharma Llc | POTENTIVE AND SELECTIVE INHIBITORS OF HEPATITIS C VIRUS |
| WO2012048421A1 (en) | 2010-10-14 | 2012-04-19 | Boehringer Ingelheim International Gmbh | Hepatitis c inhibitor compounds |
| SI2640719T1 (sl) | 2010-11-17 | 2017-07-31 | Gilead Pharmasset Llc | Antivirusne spojine |
| WO2012087976A2 (en) * | 2010-12-21 | 2012-06-28 | Intermune, Inc. | Novel inhibitors of hepatitis c virus replication |
| EP3778606A3 (en) | 2011-11-16 | 2021-03-03 | Gilead Pharmasset LLC | Condensed imidazolylimidazoles as antiviral compounds |
| US20130309196A1 (en) | 2012-05-16 | 2013-11-21 | Gilead Sciences, Inc. | Antiviral compounds |
| US9079887B2 (en) * | 2012-05-16 | 2015-07-14 | Gilead Sciences, Inc. | Antiviral compounds |
| US9233974B2 (en) | 2012-12-21 | 2016-01-12 | Gilead Sciences, Inc. | Antiviral compounds |
| US20150064252A1 (en) | 2013-08-27 | 2015-03-05 | Gilead Pharmasset Llc | Solid dispersion formulation of an antiviral compound |
| EP4005560A1 (en) | 2013-08-27 | 2022-06-01 | Gilead Pharmasset LLC | Combination formulation of two antiviral compounds |
| TW202014413A (zh) | 2014-06-11 | 2020-04-16 | 美商基利法瑪席特有限責任公司 | 製備抗病毒化合物之方法 |
| TWI721947B (zh) | 2014-06-11 | 2021-03-21 | 美商基利法瑪席特有限責任公司 | 抗病毒化合物的固態形式 |
| JP2016051146A (ja) | 2014-09-02 | 2016-04-11 | ウシオ電機株式会社 | 光検出装置 |
-
2011
- 2011-11-16 SI SI201131200A patent/SI2640719T1/sl unknown
- 2011-11-16 US US13/884,578 patent/US9156823B2/en active Active
- 2011-11-16 JP JP2013539970A patent/JP5905020B2/ja active Active
- 2011-11-16 WO PCT/US2011/060966 patent/WO2012068234A2/en not_active Ceased
- 2011-11-16 CA CA2817840A patent/CA2817840A1/en not_active Abandoned
- 2011-11-16 EP EP19215845.9A patent/EP3699176A3/en not_active Withdrawn
- 2011-11-16 KR KR1020197036217A patent/KR20190140486A/ko not_active Ceased
- 2011-11-16 NZ NZ726475A patent/NZ726475A/en unknown
- 2011-11-16 TW TW100141839A patent/TWI548629B/zh active
- 2011-11-16 ES ES11791700.5T patent/ES2634095T3/es active Active
- 2011-11-16 TW TW105118984A patent/TWI607011B/zh active
- 2011-11-16 AU AU2011328980A patent/AU2011328980B2/en active Active
- 2011-11-16 EP EP17169675.0A patent/EP3284741A1/en not_active Withdrawn
- 2011-11-16 UY UY33735A patent/UY33735A/es not_active Application Discontinuation
- 2011-11-16 SG SG10201509456SA patent/SG10201509456SA/en unknown
- 2011-11-16 TW TW106129863A patent/TWI640526B/zh active
- 2011-11-16 KR KR1020137015201A patent/KR101835474B1/ko active Active
- 2011-11-16 AR ARP110104276 patent/AR083711A1/es active IP Right Grant
- 2011-11-16 NZ NZ710567A patent/NZ710567A/en unknown
- 2011-11-16 CA CA3102625A patent/CA3102625C/en active Active
- 2011-11-16 PL PL11791700T patent/PL2640719T3/pl unknown
- 2011-11-16 KR KR1020187005807A patent/KR20180026563A/ko not_active Ceased
- 2011-11-16 KR KR1020197002491A patent/KR20190012271A/ko not_active Ceased
- 2011-11-16 KR KR1020207034568A patent/KR20200140924A/ko not_active Ceased
- 2011-11-16 CA CA3095528A patent/CA3095528C/en active Active
- 2011-11-16 EP EP11791700.5A patent/EP2640719B1/en active Active
- 2011-11-16 SG SG2013036223A patent/SG190785A1/en unknown
- 2011-11-16 PT PT117917005T patent/PT2640719T/pt unknown
-
2013
- 2013-05-13 IL IL226346A patent/IL226346A/en active IP Right Grant
-
2015
- 2015-07-30 US US14/814,392 patent/US10344019B2/en active Active
-
2016
- 2016-03-15 JP JP2016051146A patent/JP2016106149A/ja active Pending
-
2017
- 2017-04-13 AU AU2017202461A patent/AU2017202461A1/en not_active Abandoned
- 2017-12-15 JP JP2017240524A patent/JP2018039851A/ja not_active Withdrawn
-
2018
- 2018-07-24 HK HK18109580.7A patent/HK1250162A1/en unknown
-
2019
- 2019-03-20 AU AU2019201939A patent/AU2019201939C1/en active Active
- 2019-05-23 US US16/421,330 patent/US20200123132A1/en not_active Abandoned
- 2019-11-15 JP JP2019206819A patent/JP2020037584A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013542996A5 (enExample) | ||
| JP2012526838A5 (enExample) | ||
| TWI827646B (zh) | Ptpn11抑制劑 | |
| AU2015355839B2 (en) | Heterocyclic derivatives and use thereof | |
| JP6873145B2 (ja) | ５−置換２−（モルホリン−４−イル）−１，７−ナフチリジン | |
| AU2014233414B2 (en) | N-acyl-N'-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities | |
| ES2610366T3 (es) | Heterociclil-aminoimidazopiridazinas | |
| ES2648876T3 (es) | Dihidropirido[3,4-b]pirazinonas sustituidas como inhibidores duales de proteínas BET y quinasas tipo polo | |
| EA038098B1 (ru) | Тетрациклические пиридоновые соединения в качестве противовирусных средств | |
| EA006656B1 (ru) | Производные пиримидина, ингибирующие вич | |
| JP2012528166A5 (enExample) | ||
| CN107922431A (zh) | Hpk1抑制剂及其使用方法 | |
| JP2012507566A5 (enExample) | ||
| JP2013518129A5 (enExample) | ||
| JP2010539110A5 (enExample) | ||
| CN114430740A (zh) | Egfr抑制剂、组合物及其制备方法 | |
| JP2012501312A5 (enExample) | ||
| JP2017532360A5 (enExample) | ||
| JP2013544261A5 (enExample) | ||
| NZ588830A (en) | Inhibitors of protein kinases | |
| RU2010114828A (ru) | Производные урацила или тимина для лечения гепатита с | |
| PH12015502114B1 (en) | 2-aminopyrimidin-6-ones and analogs exhibiting anti-cancer and anti-proliferative activities | |
| JP2007513915A5 (enExample) | ||
| CN106065009A (zh) | 作为丙型肝炎抑制剂的化合物及其在药物中的应用 | |
| RU2014115290A (ru) | Производные 1-фенил 2-пиридинилалкиловых спиртов в качестве ингибиторов |